Dublin, Oct. 04, 2016 -- Research and Markets has announced the addition of the "Global Active Pharmaceutical Ingredients (API) Market Analysis 2016 - Forecast to 2022" report to their offering.
This report analyzes the global markets for "Active Pharmaceutical Ingredients (API)". The market assessment is performed through standard and the tailored research methodology approach.
Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.
Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.
This report provides:
- Market Sizing estimations and forecasts for a minimum of 6 years of all the given segments, sub segments and the regional markets
- Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Regional and country level market analysis
- Competitive landscaping mapping the key common trends
- Company profiling covering the financials, recent activities and the future strategies
- Supply chain trends mapping the recent advancements
- Strategic recommendations for the new entrants
Key Topics Covered:
1 Introduction
2 Executive Summary
3 Market Analysis
4 Porters Five Force Analysis
5 Active Pharmaceutical Ingredient Market by Drug type
6 Active Pharmaceutical Ingredient Market by Therapeutic Area
7 Active Pharmaceutical Ingredient Market by Type
8 Active Pharmaceutical Ingredient Market by Manfacturing Process
9 Geographical Segmentation
10 Vendor Landscaping
11 Company Profiles
- Aurobindo Pharma Ltd.
- Dr. Reddy's Laboratories Ltd.
- Teva Pharmaceutical Industries Limited
- Mylan Inc.
- Sun Pharmaceutical Industries Ltd.
- Lupin
- Allergan PLC
- Novartis International AG
- Albemarle Corporation
- Sigma-Aldrich Corporation
- WuXi AppTec
- BASF SE
- Pfizer, Inc
- Boehringer Ingelheim GmbH
- Ranbaxy
- Boehringer Ingelheim
- Lonza
For more information about this report visit http://www.researchandmarkets.com/research/mrrkmz/global_active
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals


Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Apple Turns 50: From Garage Startup to AI Crossroads
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 



